30 Jahre gesunde Energie für die gesamte Haut
Wir gestalten die Zukunft der ästhetischen Medizin weiter
(1996-2005)
The Science Comes First
The laser industry had a skin tone problem.
We spent nearly a decade solving it - engineering 650-micropulse pulse technology that made safe treatments across all Fitzpatrick skin types possible for the first time.
We chose to be right, not first.
• 1996
Aerolase founded with a singular misson: create laser technology safe for all skin types.
• 2000
First FDA clearance.
• 2004
Expanded FDA clearances across multiple indications.
• 2005
LightPod Neo & LightPod Era platforms established.
Nine years. Zero shortcuts. The science was proven before commercial pressure ever entered the equation.
We expanded geographically before we expanded commercially.Weltweite Validierung durch klinische Exzellenz.
• 2006–2011
U.S. dermatology market entry with clinical research and proof of concept.
• 2012–2015
Additional FDA clearances for Neo; Medical Advisory Board formed; peer-reviewed publications.
Every adoption was intentional. Every case study was a proof point.Wir lassen klinische Ergebnisse, nicht Marketingbudgets, die Akzeptanz vorantreiben. Die Technologie hat sich unter den anspruchsvollsten Bedingungen bewährt.
Wir expandierten geografisch, bevor wir kommerziell expandierten. Wir haben die Einführung von KOL erreicht und Fallstudien für verschiedene Patientenpopulationen weltweit erstellt.
(2006-2015)
Beweisen, dass es überall funktioniert
We didn't chase volume — we chose our first customers as carefully as we'd chosen our technology. Clinical outcomes, not marketing budgets, drove adoption.
(2016-2021)
From Clinic to the World Stage
With clinical validation in hand, we expanded internationally and launched the next generation of laser platforms.
From proof of concept to product launch.
• 2016–2017
International expansion into Europe, the Middle East, Asia and Africa.
• 2018
Neo Elite, Era Elite and Neo V launched.
• 2019–2021
North America commerical infrastructure built out.
From Technology pioneer to market leader.
• 2022
Major sales expansion across North America , Exci308 added to the Aerolase technology portfolio, business plan to target Dermatologists, Plastic Surgeons, and Aestheticians.
• 2023
Australia market development, expanded KOL network across all specialties.
• 2024
Matured sales infrastructure and market segmentation, formalized customer success programs.
• 2025
Hybrid Fractional Era launched, Aerolase India established, Era Focus in development.
(2022-2025)
Building the Engine to Scale
The science was undeniable — now we built the commercial engine to match it.
(2026+)
The Confidence Era
Proving what 30 years of precision enables.
Three decades of physics-first innovation. One unwavering commitment: healthy energy that works for every patient, every time.
The Next 30 Years
We're not just celebrating where we've been. We're defining where the industry is going!
Drei Jahrzehnte voller Wirkung
3000+
Die Praktiken dienten.
1 M
Behandelte Patienten.
50+
Länder erreicht.
I-VI
Sicher behandelte Hauttypen.
30 Years, In Their Words
„Wir haben lange nach Geräten gesucht, die für eine Vielzahl von Hauttönen sicher und wirksam sind. Für Patienten mit dunklerer Haut, die nach Haarentfernung, Verjüngung, Behandlung von Blutgefäßen oder Blutergüssen suchen, hatten wir dieses Gerät nicht wirklich, bis Aerolase auf den Markt kam. Es ist sicher und effektiv und ich kann es bei jedem Patienten anwenden.“
